About 6 results found for searched term "51-55-8" (0.133 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M7585 | Atropine | AChR/AChE |
| Tropine tropate; DL-Hyoscyamine | ||
| Atropine (Tropine tropate) is a competitive nonselective antagonist at central and peripheral muscarinic acetylcholine receptors. Atropine inhibits ACh-induced relaxations in human pulmonary veins. Atropine can be used for research of anti-myopia and bradycardia. | ||
| M16500 | Rosthornin A | Diterpenoids |
| Rosthornin A | ||
| M42512 | MMP13-IN-4 | MMP |
| MMP13-IN-4 is a potent and selective inhibitor of MMP-13 (IC50=14.6 μM), involved in osteoarthritis (OA). | ||
| M28377 | Vevorisertib trihydrochloride | Akt |
| ARQ 751 trihydrochloride | ||
| Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. | ||
| M28378 | Vevorisertib | Akt |
| ARQ 751 | ||
| Vevorisertib (ARQ 751) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations. | ||
| M56296 | CCG258747 | Opioid Receptor |
| CCG258747 is a selective GRK2 inhibitor (IC50=18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, >5500, and >550–fold, respectively).CCG258747 also blocks the internalization of the µ-opioid receptor. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
